These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Maximizing IT in smaller hospitals. Benefits of combined clinical information and cost accounting systems exceed those of either one alone. Reynolds J; Rabin J Healthc Inform; 2004 May; 21(5):49-52. PubMed ID: 15179739 [No Abstract] [Full Text] [Related]
25. Formulary decision-making considerations: COX-2 inhibitors. Shaya FT; Wong W; Shin JY; Martin L; Samant N Manag Care Interface; 2004 Nov; 17(11):29-36, 41. PubMed ID: 15573802 [TBL] [Abstract][Full Text] [Related]
26. Is it worth the trouble? The new policy on dissemination of information on off-label drug use under the Food and Drug Administration Modernization Act of 1997. Weeks EA Food Drug Law J; 1999; 54(4):645-65. PubMed ID: 11824459 [No Abstract] [Full Text] [Related]
28. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results. Falit BP Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220 [No Abstract] [Full Text] [Related]
29. Drug information resources for health professionals and consumers. Durkin C Natl Netw; 1998 Feb; 22(3):10-1. PubMed ID: 10176590 [No Abstract] [Full Text] [Related]
30. How one award team makes its decisions. Hosp Peer Rev; 1999 May; 24(5):77-9. PubMed ID: 10623129 [No Abstract] [Full Text] [Related]
31. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Anell A; Persson U Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561 [TBL] [Abstract][Full Text] [Related]
32. Role of technology assessment in health benefits coverage for medical devices. Braslow NM; Shatin D; McCarthy DB; Newcomer LN Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990 [TBL] [Abstract][Full Text] [Related]
33. FDA restructures new product review centers. Bouchie A Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100 [No Abstract] [Full Text] [Related]
34. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition. Kraushaar KJ Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581 [No Abstract] [Full Text] [Related]
35. The big gap at the FDA. Stipp D Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178 [No Abstract] [Full Text] [Related]
36. Developing business opportunities in a provider-sponsored organization. Allen B; Sharar D Behav Healthc Tomorrow; 1999 Apr; 8(2):45-7, 50. PubMed ID: 10351301 [No Abstract] [Full Text] [Related]
37. Use of health-related quality of life information in managed care formulary decision-making. Wu WK; Sause RB; Zacker C Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497 [TBL] [Abstract][Full Text] [Related]
38. Use of randomized controlled trials in organizational decision making: a cost-minimization approach. Cher DJ; Maclure M Am J Manag Care; 2000 Aug; 6(8):894-904. PubMed ID: 11186501 [No Abstract] [Full Text] [Related]
39. The pharmacoeconomics of high-cost biotechnology products. Dana WJ; Farthing K Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236 [TBL] [Abstract][Full Text] [Related]
40. Managed care guidelines for the economic evaluation of pharmaceuticals. Langley PC; Martin RE Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]